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INTRODUCTION
Haemophilus influenzae type b (Hib) is an important cause
of meningitis, pneumonia, and other invasive infections in
infants (1-3). Hib meningitis, specifically, may result in seri-
ous neurological sequelae. Invasive diseases caused by Hib
can now be prevented by immunization with polysaccha-
ride-protein conjugate vaccines that were developed in the
1980s and are proven safe, immunogenic, and highly effec-
tive when given to infants (3). Until now, the Hib vaccines
have not been added to the routine immunization schedules
of developing countries because of the high cost of the vac-
cine and low economic efficiency (4). Among 37 Western
Pacific region countries, only 16 countries have introduced
the Hib vaccine into their routine childhood immunization
program in 2005 (5). Mongolia introduced and supported
the conjugate Hib vaccine with the support of the Global
Alliance for Vaccines and Immunization (GAVI) in 2005.
Indonesia included Hib vaccine into their national immu-
nization program after the research on cost-benefit analysis
of Hib immunization (6). 
In Korea, the conjugate Hib vaccine was introduced in
1993 but has not yet been integrated into the national immu-
nization program. The cost of Hib immunization is not sup-
ported by the Korean government, because it is not included
in the national immunization program, meaning that the
total cost of Hib immunization has to be paid by parents. The
total direct cost of Hib immunization for a full series of 3
doses is 120,000 won, imposing a heavy burden on parents.
Despite this fact, the Hib immunization rate has risen from
16% in 2002 (7) to 50% in 2005 (8).
Since 1998, the World Health Organization (WHO) has
recommended that the Hib conjugate vaccine be included
in national immunization schedule in all countries where
resources permit its use and the burden of disease has been
established (1, 3).
To examine whether Hib immunization should be includ-
ed in a universal immunization program in Korea, an eco-
nomic evaluation of Hib immunization was conducted with
societal perspective. All future costs associated with long-term
health effect from Hib disease were considered.
MATERIALS AND METHODS 
Epidemiological data and model 
The epidemiological data on Hib for Korea were obtained
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Cost-Benefit Analysis of Haemophilus Influenzae Type B Immunization
in Korea
An economic evaluation of Haemophilus influenzae type b (Hib) immunization was
conducted to examine whether Hib immunization should be included in the Korea’s
national immunization program. The costs and benefits included direct and indirect
values and an estimation of the economic efficiency. We determined that a univer-
sal Hib immunization program in Korea would prevent 17 deaths and 280 invasive
Hib cases. When we assumed the one Hib immunization cost as 26,000 won, the
national Hib immunization would cost 34.6 billion won. Costs for various Hib dis-
eases were estimated at 26.8 billion won (11.8 billion won from direct costs and
14.9 billion won from indirect costs). A benefit-cost ratio of 0.77 showed that the
economic efficiency of the integration of Hib immunization in Korea is low because
of the low incidence rate of Hib disease and high price of vaccine. However, if the
Hib immunization cost decrease to less than 20,000 won, a benefit-cost ratio in-
crease to 1.0 and above, integrating Hib immunization into the national immuniza-
tion program with economic efficiency can be considered.
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from the results of a previously published paper. Results from
other Asian countries and Western countries were also used
in our analysis. A decision tree of the cost-benefit analysis is
presented in Fig. 1. 
The economic effect of the Hib immunization program
on a birth cohort of 493,471 infants, the estimated number
of births in 2003, was evaluated from birth through to 5 yr
of age. The most important epidemiologic data used in this
cost-benefit analysis were based on the results of Kim and
his colleagues’ survey in 2004 (7). This was the first popula-
tion-based study and the only report of annual incidence of
Hib meningitis in Korea; it was conducted between 1999
and 2001 in Jeonbuk province. The annual incidence of Hib
disease was estimated at 6.8 per 100,000 in children under
the age of 5. This study assumed that 16% (7) of children
on the study population were completely immunized with
the Hib vaccine. Therefore, they estimated the Hib incidence
based on an adjusted population denominator that did not
include children with the Hib vaccination since they would
not be at risk for the Hib disease. We used the adjusted annual
incidence of Hib invasive disease in the analysis, which was
8.1 per 100,000 in children under 5 yr of age (7). Among
Hib invasive disease, 87% showed meningitis (the incidence
of Hib meningitis was 7.1 per 100,000), and 13% caused
other invasive disease including pneumonia, epiglottitis, and
other manifestations (7). We could not find data on the inci-
dence rates of Hib pneumonia and other Hib invasive dis-
eases except Hib meningitis in Korea, so we assumed the
same ratios for pneumonia over meningitis as those gathered
from the United States (9) because the US data were very
comprehensive than the other countries data. The case fatal-
ity rate of Hib meningitis was 7% (7). Hib meningitis is a
dangerous disease associated with a high rate of neurological
sequelae; possible long-term consequences for children with
meningitis included in our model were mental retardation,
severe hearing loss, epilepsy, and hemiplegia. The probabili-
ties of these outcomes were 6.1%, 6.7%, 6.1%, and 5.1%,
respectively (9, 10). Current Hib vaccine is highly effective
(3). Therefore, in this study, we assumed Hib vaccine effica-
cy after completing the immunization schedule set at 99%
(11, 12) and 100% compliance for cost-benefit analysis. The
epidemiological data used in the economic evaluation are
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Fig. 1. Hib immunization decision tree.
*National Statistical Office (NSO), Population report 2004.
Variable Value Reference
Hib diseases incidence  8.1/10
5 (7)
per 100,000 children <5 yr old
Case fatality rate (for meningitis) 7% (7)
Probability of sequelae 
Hemiplegia 5.1% (9)
Hearing loss 6.7% (9)
Epilepsy 6.1% (9)
Mental retardation 6.1% (9)
Annual birth cohort (person) 493,471 NSO*
Vaccine efficacy 99% (11, 12)
Immunization coverage rate 90% (8)
Immunization schedule  2nd, 4th, and  (3)
12-15th month
Table 1. Summary of the variables used to estimate the outcomes
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listed in Table 1. 
Discounting
Costs were expressed in Korean won (1 USD=1,200 won
[exchange rate in 2003]). All costs were inflated to the value
of the Korean won in 2003, and discounted at a 5% annual
rate for the base case analysis by Center for Disease Control
and Prevention (CDC)’s recommendation (13).
Sensitivity analysis
An economic evaluation was conducted to evaluate the
introduction of a prevention program by universal immu-
nization against Hib in infants less than 1 yr of age in Korea.
A sensitivity analysis was also performed to evaluate the
robustness of the conclusion to changes in the assumptions
about the main determinants of costs and benefits to prevent-
ing the Hib invasive disease. We changed price of Hib vac-
cination, discount rate, and the incidence of Hib disease. For
the discount rate, we used a 3% discounted rate, according
to Korean pharmacoeconomics guidelines (K-PEG) devel-
oped by the Health Insurance Review and Assessment ser-
vice (HIRA) in 2005.
Given the limited information on Hib disease incidence in
Korea, to evaluate the extent to which underestimation of
Hib incidence rate in the pre-immunization era could poten-
tially have an impact in our analysis, a 95% confidence inter-
val (4.1/100,000-16.1/100,000) of the 8.1/100,000 incidence
rate was used in our model (7).
Costs of Hib diseases 
In this study, direct costs included those associated with
the medical cost of Hib diseases, additional costs due to
sequelae of Hib meningitis and transportation. Indirect costs
included the economic value of the lives of children and par-
ents due to Hib diseases and sequelae. The benefit of the
immunization program is conceptualized as those costs that
would be avoided with Hib immunization. Benefit includ-
ed not only the averted medical costs associated with acute
Hib disease and sequale, but also the reduced economic pro-
ductivity that results from a disability or premature death.
Table 2 shows the value of economic parameters used for cost-
benefit analysis.
The National Health Insurance (NHI) program in Korea
covers the whole population as a compulsory social system;
the total number of people covered by the NHI reached over
47 million or about 96.6% of the total population. Medical
costs including inpatient and outpatient cases of Hib menin-
gitis, Hib pneumonia, and other Hib diseases were calculat-
ed using the HIRA claim data from 2003. Because these
data included only insurance covered costs, we also include
non-reimbursed costs (14) in the medical calculation (non-
reimbursed costs in total health care expenditure was 15.4%
for inpatient and 30.1% for outpatient) (14). The average
medical costs were estimated to be 3,040,399 won for menin-
gitis, 1,228,269 won for pneumonia, and 1,284,995 won
for all other types of Hib invasive diseases including epiglot-
titis, bacteremia, and cellulitis.
Hib meningitis can cause neurological disabilities such as
mental retardation, hearing loss, and epilepsy, and we includ-
Variable Cost (Korean won) Data and assumption
Cost for medication Meningitis: 3,040,399  Based on HIRA claim data
Pneumonia: 1,228,269 Non-reimbursement cost included
Others: 1,284,995
Cost for sequelae (per year) Hemiplegia: 3,600,000 Medical cost for 50 yr
Mental retardation: 8,400,000  Special education for 15 yr
Hearing loss: 250,000 Hearing aid replaced every 5 yr
Epilepsy: 1,343,000 Medical cost for 50 yr (3.6% inflation rate and 5% discount rate)
Transportation 3,529/day 2001 KNHANES data were converted to the 2003 won applying CPI
Loss of parent income  Income loss: 101,895/day Average wage from the survey 
(while the children are in hospital) Meningitis: 38.2 days report on the wage structure 
Pneumonia: 19.1 days of the ministry of labor
Others: 15.9 days Economically active population rate was weighted
Loss of parent income  2,037,894/month Income loss for 37 yr with a 10% increase every 5 yr 
(children with sequelae) Other conditions were same
Loss of children’s future income  2,037,894/month Income loss for 47 yr with a 10% increase every 5 yr; HUI
(children with sequelae) (hearing loss: 0.977 and other sequeale: 0.840) applied
Loss of children’s future income  2,037,894/month Income loss for 47 yr with a 10% increase every 5 yr
(deceased children)
Hib vaccine 26,000/shot 20,000 (vaccine)+6,000 (administration)
Table 2. Summary of the data and assumption used for cost-benefit analysis
See Appendix for detail assumptions and methods for estimation.
HIRA, health insurance review agency; KNHANES, Korea National and Nutrition Examination Survey; CPI, consumer price index; HUI, health utility index.Cost-Benefit Analysis of H. influenzae type b immunization in Korea 179
ed the cost of associated rehabilitation services in this study.
Concretely, it was assumed that the annual costs for hemiple-
gia, which accounted for 5.1% of Hib meningitis cases, were
3,600,000 won based on National Rehabilitation Center
(NRC) data, and that the average lifespan is 50 yr for these
individuals (9). For children with hearing impairments, the
cost of a hearing-aid was included. The cost of a standard hear-
ing-aid used was the benefit paid by the Ministry of Health
and Welfare (MOHW) health security program, which was
paid at 250,000 won. This study assumed that the patient
would need a hearing-aid for 50 yr of life and it would have
to be replaced every 5 yr. For long-term epilepsy care, the
annual treatment cost was 1,343,000 won based on HIRA
data, and it was calculated for 50 yr. The average monthly
special education cost for mentally handicapped children until
19 yr old was 700,000 won based on data from the Research
Institute for Differently Abled Person’s Right in Korea (RI-
DRIK). We assumed that this kind of special education would
be needed for 15 yr, from age 5 to 19. The cost associated with
rehabilitation for sequelae was inflated at 3.6%, discounted
at a 5% annual rate and was expressed at the 2003 rate for
the won. Other direct costs for treatment include the care-
giver’s travel cost to clinics during the treatment period (a
round- trip in Seoul). We calculated the average cost of trans-
portation using 2001 Korea Health and Nutrition Examina-
tion Survey (KNHANES) data, and then we converted it to
the 2003 won rate, applying the Consumer Price Index (CPI)
for transportation. 
Our model estimated the economic value of life lost pre-
maturely, indirect costs from permanent disability, and indi-
rect costs associated with parents who missed work and stay-
ed at home to care for sick children. Although difficulty to
estimate, the economic value of life was estimated using the
human capital approach that assumes that the monetary
value of lost productivity equals the wage rate (15). 
The indirect costs associated with parents’ absence from
work to take care of their sick children with Hib were includ-
ed in the analysis. The economic costs for parents taking time
off work were estimated on the basis of individual inpatient
and outpatient days and an average daily wage of 101,895
won in 2003. The average wage data were taken from the
Survey Report on Wage Structure of the Ministry of Labor
(16). The average treatment periods of Hib invasive disease
inpatients and outpatients, respectively, were 23.6 days and
14.6 days for meningitis, 16 days and 3.1 days for pneumo-
nia, and 13.7 days and 2.2 days for other Hib diseases. The
period of treatment was based HIRA claim data. Addition-
ally, costs incurred by parents whose child had Hib menin-
gitis sequelae were calculated as follows: it was assumed that
full-time care would have to be provided by a parent at an
average annual earning of 24.4 million won (16) for 37 yr
from the age of 30 (17) - average age of parent at the birth of
their first child - up to the age of 67, with a 10% increase every
5 yr. This information was used to calculate the future earning
of an individual. The average age of retirement was assumed
to be 67 yr of age in Korea based on the 2003 Organization
for Economic Cooperation and Development (OECD) report. 
For cases where the child has sequelae, the loss of income
under the assumption from the age of 20 (the average age of
people when they get their first job), up to the age of 67 was
estimated. To adjust the severity of disability due to Hib,
the Health Utility Index (HUI) (18) was applied to the cal-
culation: 0.840 for hemiplgia, epilepsy, and mental retarda-
tion and 0.977 for severe hearing loss (19). The HUI is a value
assigned to the quality of life, calculating a weighted coeffi-
cient for each health state and adopted in relation to the age
of patient. The cost related to a loss of productivity resulting
from premature death was also estimated for 47 yr. Since not
everyone will be employed, the economically active popula-
tion rate of 74.7% (20) from the National Statistical Office
(NSO) was weighted in the calculation of productivity loss
(Table 2).
Costs of the universal immunization program
Hib immunization could be safely administrated with
other vaccines such as vaccine for diphtheria, tetanus and
pertussis (DTP), and polio immunizations, so the establish-
ment of a Hib immunization program would share infras-
tructure and organizational costs with the existing immu-
nization program. Therefore, the marginal cost for extending
the existing program for DTP and polio immunizations was
estimated as an indirect costs of the immunization (6, 9, 11,
21, 22). That is to say, there would be no added cost for an
extra visit to the clinic for the Hib vaccine injection. 
There are many different combination vaccines that con-
tain the Hib conjugate vaccine; Hib combined with DTP,
hepatitis B, and polio. However, combination vaccines were
not considered in this study because of the price of vaccine,
the schedule and number of immunization, and the efficacy
of combination vaccines vary by vaccine. 
The number of immunizations needed with the Hib con-
jugate vaccine is 3 to 4 as stated by the manufacturer. We
assumed 3 shots for the Hib immunization in this study. 
The following items were considered in estimating the
cost of the immunization program: costs for immunization
and treatment of adverse reactions produced by the vaccine
for direct costs; and the indirect costs included missed work
on the part of the parent in the case of an adverse reaction. 
Hib vaccine is more expensive than the traditional expand-
ed program on immunization (EPI) vaccine, and prices are
changing and differ among countries (3). Hib vaccines are
only administered by private clinics in Korea. The price of
the Hib immunization is 40,000 won which includes the
vaccine and administrative cost; the vaccine cost is around
27,000-30,000 won (whole-sale price) and the administra-
tive and other cost is around 10,000 won in 2003. However,
if Hib immunization is adopted as one of the routine immu-180 S. Shin, Y.-J Shin, M. Ki
nization and administrated in public clinics, the price would
decrease. Hib immunization schedule is same as DTP immu-
nization schedule; they can get Hib and DTP together at
one visit which can decrease the administrative cost. When
the vaccine purchased by public health sector, the cost of
vaccine also can be decreased. It was assumed that there would
be a 50% reduction of administrative costs and 20% reduc-
tion of the cost of the vaccine. Therefore, we estimated 26,000
won per dose with a 35% reduction of the current price in
2003 for a universal immunization program in the base anal-
ysis. The coverage rate of universal immunization was assum-
ed at 90% in this study.
Conjugate Hib vaccines have been found to be generally
well-tolerated. They are probably the least reactogenic vac-
cines in current use, since data from vaccine trials and sever-
al large post-marketing surveillance studies have indicated
that serious reactions attributable to Hib vaccines are rare
(23, 24). Therefore, no medication costs or indirect costs of
a patient’s time due to adverse vaccine reactions were assumed.
RESULTS
In the base analysis, the universal immunization program
would prevent 280 cases of invasive disease, 17 deaths, and
59 sequelae from Hib meningitis. The cost per death avert-
ed would be 2 billion won, 123 million won per Hib case
averted, and 587 million won per case of Hib meningitis
sequelae averted (Table 3).
When we assumed the cost for one shot of Hib immuniza-
tion as 26,000 won, the immunization program would result
in a cost of about 34.6 billion won. The cost for Hib disease,
which is regarded as benefits by Hib immunization, was esti-
mated 23.8 billion won (11.8 billion won from direct benefit
and 12.0 billion won from indirect benefit). Therefore, a net cost
was 7.9 billion won (34,641,664,000 won-26,708,274,000
won=7,933,390,000 won) and a benefit-cost ratio was 0.77
(26,708,274/34,641,664=0.77). This means that the bene-
fits incurred by Hib immunization would be less than its
costs. It was shown that integrating the Hib immunization
into our national immunization program with the present
price of vaccine and incidence of Hib disease has a low eco-
nomic efficiency (Table 3).
The sensitivity analysis showed that the results are closely
related to the incidence of Hib; the benefit-cost ratio was
less than 1 (0.39) in the low limit of incidence rate, and the
benefit-cost ratio was higher than 1 (1.53) in the case of a
high limit of incidence rate (Table 4). In the reference inci-
dence of Hib disease, we found the maximum price that would
make it cost-beneficial was 20,000 won. The benefit-cost
ratios of Hib immunization varied from 0.25 to 1.99 using
a 5% discounted rate and from 0.31 to 2.46 using a 3% dis-
counted rate. 
Component
Cost (1,000
Korean won)
Benefit
Cost for medication 776,421
Cost for sequelae 11,012,512
Transportation 34,620
Loss of parent income   746,715
(while the children are in hospital)
Loss of parent income (children with sequelae) 2,927,331
Loss of children’s future income   3,301,591
(children with sequelae)
Loss of children’s future income (deceased children) 7,909,084
Total 26,708,274
Cost
Immunization (vaccine+administration) 34,641,664
Total 34,641,664
Cost per life saved 2,037,745
Cost per case averted 123,720
Cost per sequlae averted 587,147
Net cost 7,933,390
Benefit/cost ratio 0.77
Net benefit per vaccine 20
Table 3. Expected benefit and cost for Hib to 2003 birth cohort
in Korea
Hib immunization 
cost (Korean won)
Discount 
rate (%)
Incidence of Hib disease*
4.1/
100,000
8.1/
100,000
16.1/
100,000
20,000 3 0.63 1.24 2.46
5 0.51 1.00 1.99
26,000
� 3 0.48 0.95 1.90
5 0.39 0.77 1.53
40,000
� 3 0.31 0.62 1.23
5 0.25 0.50 1.00
Table 4. Sensitivity analysis of benefit-cost ratio
*8.1/100,000 was cited from reference (7), and the 95% confidence inter-
val of this incidence was 4.1/100,000-16.1/100,000; 
� Assumed cost for
universal immunization; 
� Cost in private clinics in 2003.
Hib, Haemophilus influenzae type b.
Setting Benefit-cost ratio Incidence rate* Reference
U.S.A. 5.40 113.7 (9) 
3.57 42.0 (34)
Chile 1.66 43.0 (34)
Israel 1.45 183.7 (34)
Slovenia 1.39 16.4 (34)
South africa 1.29 133.0 (34)
Malaysia 1.09 37.0
� (6) 
Spain 0.89 15.0 (11) 
Table 5. Comparison of cost-benefit analysis of Hib immunization 
*Incidence rates of all invasive Hib disease for infants under 5 yr of age
(per 100,000); 
� Incidence rates of Hib meningitis.
Hib, Haemophilus influenzae type b. Hib, Haemophilus influenzae type b.Cost-Benefit Analysis of H. influenzae type b immunization in Korea 181
DISCUSSION 
Even though WHO has recommended that the Hib con-
jugate vaccine be included in national immunization sched-
ules in all countries, the MOHW of Korea did not include
Hib immunization as a national routine immunization pro-
gram, because there were no data on cost-benefit analysis
and the cost of immunization is very expensive. All Hib vac-
cines used in Korea are imported and the cost of the Hib vac-
cine in 2003 was more than 7,136,989 USD for one year
(25), and the voluntary coverage rate of Hib immunization
reached 50% (8). Thus, Korea’s vaccine policy for Hib should
be reconsidered and a reasonable guideline should be prepared
by the Korean government.
The results of the economic evaluation of Hib immuniza-
tion in this study showed Hib immunization would be ben-
eficial with a cost less than 20,000 won for one shot of immu-
nization. However, the price in 2003 (26,000 won for one
shot) showed a low economic efficiency. The relatively a lower
economic efficiency of Hib immunization in Korea resulted
mainly from the low incidence rate. Most economic evalua-
tions of Hib immunization showed that the results were very
sensitive to the incidence of Hib disease (6, 11, 21, 22). This
result differs from those of most other countries (Table 5).
Most economic evaluations of Hib immunization have shown
that the benefit exceeds the cost of Hib immunization, except
in Spain (11). 
Some aspects must be considered in the interpretation of
these results. The incidence rate used in this study, which was
firstly reported and unique in Korea, was the lowest among
the countries studied. Additionally, incidence rates of Hib
pneumonia and other Hib diseases have not yet been report-
ed, and we had to assume them using Hib epidemiology data
from the United States. The US data was more comprehen-
sive and detail than data from other countries; however, the
epidemiological condition could be different from that in
Korea. Although we used an adjusted incidence rate, there is
a possibility that the incidence was underestimated due to
the introduction of the Hib vaccine in private sectors. Inci-
dence rates in this study were lower than those reported in
the US, Northern Europe, and Australia in the pre Hib con-
jugate vaccine era (26), but are comparable to rates observed
elsewhere in Asia. The low incidence rate of Hib diseases as
found in Korea were also observed in other Asian countries,
such as China (27-29) and Japan (30, 31). The variation in
Hib diseases incidence rates in different countries and in
regions of the same country may be due to the substantial
heterogeneity in healthcare systems, completeness of surveil-
lance, methods for clinical evaluation, treatment practices,
and socioeconomic determinants. At any rate, it seems true
that Hib meningitis rates in Asia are much lower than those
in the Western countries such as US and Europe. As for the
possible reasons for the low rate of Hib disease among Asian
children, inadequate case ascertainment and poor microbi-
ology have been suggested (32). Other invasive diseases caus-
ed by Hib, in addition to bacterial meningitis, include bac-
terial pneumonia, cellulites, septic arthritis, and epiglottis.
It was difficult to find the incidence rate of these syndromes
in Asian countries (5). Additional studies examining the
incidence rate of Hib disease and why some Asian countries
show a lower incidence rate of Hib are needed. 
Another reason for the lower benefit-cost ratio result was
due to the high price of Hib immunization. In Korea, the
Hib vaccine is administered in private clinics, so it was diffi-
cult to accurately account for the cost of Hib immunization.
Consequently, the immunization costs in this study were based
on the price of Hib immunization in the private sector in
2003. If the Hib vaccine is adopted as part of a routine immu-
nization, the cost for both the vaccine and its administration
would decrease. We assumed 65% of the current price for
Hib immunization in 2003; a 20% reduction of vaccine cost
and 50% reduction of administration cost. The Hib vaccine
could be purchased for around USD 20.00 in Korea, and it
is still higher than other countries’ immunization costs. How-
ever, if the Hib immunization was adopted in a national im-
munization schedule, the cost of the vaccine would proba-
bly be lower due to the economy of scale. If the cost of immu-
nization per dose could be decreased from 40,000 won to
20,000 won with the integration of Hib immunization into
the universal immunization program in Korea, we could
expect the economic efficiency to increase significantly. Korea
experienced a reduction in cost of the varicella vaccination
after it was included in the national immunization schedule
in 2005; the cost decreased by 57% in private clinics (from
35,000 won to 20,000 won) and the cost of immunization
in public health institutions was 10,000 won in 2005. There-
fore, the Hib vaccine cost per dose also is expected to decrease
significantly - more than assessed in this analysis. If the Hib
vaccination cost is under 20,000 won, the result will mean
economic efficiency. Hib immunization coverage rates have
risen from 16% in 2002 to 50% in 2005. The vaccine vol-
unteer coverage rate is high in proportion to the low inci-
dence because pediatricians in private clinics encourage Hib
vaccination. Even though public health center provide nation-
al immunization program free of charge, half of all vaccina-
tions in Korea are administered in private clinics. The rea-
sons for the high coverage rate in private clinics are due to the
accessibility and mistrusts for public health institutions.
The costs of morbidity and mortality of meningitis are
lower than in other countries due to the NHI program. The
government strongly regulates the charge of medical treat-
ment offered through NHI, so the medical and rehabilita-
tion costs are quite low; even the medical charge is lower than
prime cost in some cases. The cost in Korea is presumed to
be much lower than it that in the US: the medical cost of Hib
meningitis per patient was 2,533 USD in Korea compared
to 9,756 (9) in the US. 
The HIRA data used in this analysis do not include data182 S. Shin, Y.-J Shin, M. Ki
of non-reimbursed cost of insurance and the other costs such
as dietary supplements and over-the-counter pharmacy medi-
cines paid by patients. The validity of data is also debatable.
Despite these limitations, the NHI program that covered
the whole population as a compulsory social system is the
most representative data to calculate the medical cost.
In this study, we used human capital approach to estimate
productivity loss. However, it is quite controversial that human
capital approach could overestimate productivity loss. In this
context, the friction cost method that have been made for
Netherlands was proposed, and it give estimates of lost pro-
duction much lower than those obtained from traditional
methods, such as the human capital approach (15). Also,
Goeree et al. (33) compared the human capital and friction
cost approaches in estimating the productivity costs due to
premature mortality from schizophrenia in Canada; the esti-
mates using the human capital approach were 69 times higher
those obtained using the friction cost approach. According
to these results, the productivity loss using the human capi-
tal approach could be higher than when using the friction
cost approach, and then the results of this cost-benefit anal-
ysis would change to less cost beneficial; the benefit-cost ratio
would decrease to about 0.51. Despite this limitation, this
analysis in Korea is comparable with the Hib vaccination
cost-benefit analysis using the human capital approach in
other countries (34), and it was used almost the same method-
ology and assumption.
Hib disease is very serious and the Hib vaccine efficacy was
reported to be 99% (12). The most effective method to decrease
the Hib disease burden is Hib immunization. To decrease
Hib disease burden with increased vaccination coverage, Hib
immunization should be integrated into the national immu-
nization program. The Hib vaccine price, however, is too
high to get more benefit than the cost. If the Hib immuniza-
tion cost decrease to less than 20,000 won, a benefit-cost
ratio increase to 1.0 and above, integrating Hib immuniza-
tion into the national immunization program with econom-
ic efficiency can be considered.
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Appendix 
Calculation
Cost for medication 
=unit cost for Hib invasive disease (Table 2)×incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)
Cost for sequelae 
=unit cost for meningitis sequelae (Table 2)×probability of sequelae (Table 1)×life span (Table 2)×inflation rate (Table 2)×discount rate (Table 2)
Transportation 
=unit cost for transportation (Table 1)×incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)×treatment period (Table 2)×CPI
Loss of parent income (while the children are in hospital) 
=income per day (Table 2)×incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)×treatment period (Table 2)×74.7%*×HUI
weight (Table 2)
Loss of parent income (children with sequelae) 
=incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)×probability of sequelae (Table 1)×income per month (Table 2)×37 yr
×10% of income increase per 5 yr (Table 2)×74.7%*×HUI weight (Table 2)×discount rate (Table 2)
Loss of children’s future income (children with sequelae) 
=incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)×probability of sequeale  (Table 1)×income per month (Table 2)×47 yr
×10% of income increase per 5 yr (Table 2)×74.7%*×HUI weight (Table 2)×discount rate (Table 2)
Loss of children’s future income (deceased children) 
=incidence of disease (Table 1)×No. of children (2003 cohort, <5 yr old)×case fertility rate for meningitis (Table 1)×income per month (Table 2)×
47 yr×10% of income increase per 5 yr (Table 2)×74.7%*×discount rate (Table 2)
Immunization 
=unit cost for immunization (Table 2)×No. of children (2003 cohort, <5 yr old)×coverage rate (Table 1)×3 times (Table 1)
Table A. Detail of cost and benefit estimation 
*Economically active population rate.